1. Home
  2. FSCO vs NVAX Comparison

FSCO vs NVAX Comparison

Compare FSCO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSCO
  • NVAX
  • Stock Information
  • Founded
  • FSCO 2013
  • NVAX 1987
  • Country
  • FSCO United States
  • NVAX United States
  • Employees
  • FSCO N/A
  • NVAX N/A
  • Industry
  • FSCO Trusts Except Educational Religious and Charitable
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FSCO Finance
  • NVAX Health Care
  • Exchange
  • FSCO Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • FSCO 1.4B
  • NVAX 1.3B
  • IPO Year
  • FSCO N/A
  • NVAX 1995
  • Fundamental
  • Price
  • FSCO $6.76
  • NVAX $8.62
  • Analyst Decision
  • FSCO
  • NVAX Hold
  • Analyst Count
  • FSCO 0
  • NVAX 5
  • Target Price
  • FSCO N/A
  • NVAX $9.80
  • AVG Volume (30 Days)
  • FSCO 709.7K
  • NVAX 4.6M
  • Earning Date
  • FSCO 01-01-0001
  • NVAX 11-11-2025
  • Dividend Yield
  • FSCO 11.44%
  • NVAX N/A
  • EPS Growth
  • FSCO N/A
  • NVAX N/A
  • EPS
  • FSCO N/A
  • NVAX 2.54
  • Revenue
  • FSCO N/A
  • NVAX $1,078,718,000.00
  • Revenue This Year
  • FSCO N/A
  • NVAX $60.81
  • Revenue Next Year
  • FSCO N/A
  • NVAX N/A
  • P/E Ratio
  • FSCO N/A
  • NVAX $3.38
  • Revenue Growth
  • FSCO N/A
  • NVAX 9.22
  • 52 Week Low
  • FSCO $4.08
  • NVAX $5.01
  • 52 Week High
  • FSCO $6.00
  • NVAX $11.55
  • Technical
  • Relative Strength Index (RSI)
  • FSCO 45.96
  • NVAX 50.03
  • Support Level
  • FSCO $6.28
  • NVAX $8.02
  • Resistance Level
  • FSCO $6.64
  • NVAX $8.83
  • Average True Range (ATR)
  • FSCO 0.21
  • NVAX 0.48
  • MACD
  • FSCO -0.01
  • NVAX -0.08
  • Stochastic Oscillator
  • FSCO 55.68
  • NVAX 34.39

About FSCO FS Credit Opportunities Corp.

FS Credit Opportunities Corp is a closed-end management investment company. The Fund's primary investment objective is to generate an attractive total return consisting of a high level of current income and capital appreciation, with a secondary objective of capital preservation. It predominantly invests in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments. The credit instruments in which it invests typically are rated below investment grade by rating agencies or would be rated below investment grade if rated. To achieve its investment objectives, the fund focuses on strategies such as Opportunistic Credit, Special Situations, and Capital Structure Solutions.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: